HeartSciences Inc. (Nasdaq: HSCS; HSCSW), a leader in artificial intelligence (AI)-powered medical technology, has announced its financial results for the second quarter of fiscal year 2025, ending October 31, 2024. The company has made notable progress in the field of AI-ECG, particularly with its MyoVista® wavECGTM device and MyoVista® InsightsTM cloud-native platform.
-
Next-Gen ECG Technology: HeartSciences is at the forefront of developing next-generation ECG device hardware, cloud-native software, and AI-ECG algorithms. This initiative aims to modernize the ECG industry, which currently relies on outdated technology and legacy systems.
-
MyoVista Insights Platform: Significant advancements have been made on the MyoVista Insights platform, with Phase 1 expected to be completed by the end of 2024. This phase involves the development of a cloud-native ECG reporting system on Amazon Web Services (AWS), designed to enhance ECG reporting significantly. Phase 2, which will introduce AI-ECG reporting, is targeted for regulatory clearance in the second half of 2025.
-
AI-ECG Algorithms: The company plans to operate the MyoVista Insights platform like an app store for AI-ECG, incorporating both company-developed and third-party algorithms. This approach is intended to reduce development costs and regulatory burdens, facilitating the rapid introduction of a wide range of AI-ECG algorithms into clinical practice.
HeartSciences' efforts represent a significant step forward in the application of AI technology to improve the detection and management of heart disease, with the potential to impact healthcare settings globally.
